<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39133434</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1182</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>Molecular neurobiology</Title><ISOAbbreviation>Mol Neurobiol</ISOAbbreviation></Journal><ArticleTitle>A Disease Hidden in Plain Sight: Pathways and Mechanisms of Neurological Complications of Post-acute Sequelae of COVID-19 (NC-PASC).</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12035-024-04421-z</ELocationID><Abstract><AbstractText>The global impact of coronavirus disease 2019 (COVID-19) marked by numerous pandemic peaks is attributed to its high variability and infectious nature, transforming it into a persistent global public health concern. With hundreds of millions of cases reported globally, the illness is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite its initial classification as an acute respiratory illness, recent evidence indicates that lingering effects on various bodily systems, such as cardiovascular, pulmonary, nervous, gastrointestinal (GI), and musculoskeletal, may endure well beyond the acute phase. These persistent manifestations following COVID-19, commonly known as long COVID, have the potential to affect individuals across the entire range of illness severity, with a tendency to be more prevalent in mild to moderate cases. At present, there are no established criteria for diagnosing long COVID. Nonetheless, it is conceptualized as a multi-organ disorder encompassing a diverse array of clinical manifestations. The most common, persistent, and debilitating symptoms of long COVID may be neurological, known as neurological complications of post-acute sequelae of COVID-19 (NC-PASC). More than one-third of individuals with a prior SARS-CoV-2 infection show involvement of both the central nervous system (CNS) and peripheral nervous system (PNS), as evidenced by an approximately threefold higher incidence of neurological symptoms in observational studies. The persistent neurological symptoms of long COVID encompass fatigue, headache, cognitive decline, "brain fog", dysautonomia, neuropsychiatric issues, loss of smell (anosmia), loss of taste (ageusia), and peripheral nerve problems (peripheral neuropathy). Reported pathogenic mechanisms encompass viral persistence and neuro-invasion by SARS-CoV-2, neuroinflammation, autoimmunity, coagulopathy, and endotheliopathy. Raising awareness of potential complications is crucial for preventing and alleviating the long-term effects of long COVID and enhancing the prognosis for affected patients. This review explores the hypothetical pathophysiological mechanisms and pathways of NC-PASC with a sole aim to increase awareness about this crippling disease.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saxena</LastName><ForeName>Apoorva</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biology, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany. apoorva.saxena@campus.lmu.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mautner</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Virology, Helmholtz Zentrum M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Neurobiol</MedlineTA><NlmUniqueID>8900963</NlmUniqueID><ISSNLinking>0893-7648</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">NC-PASC</Keyword><Keyword MajorTopicYN="N">Neurological symptoms</Keyword><Keyword MajorTopicYN="N">Pathophysiological mechanisms</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>12</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>12</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>12</Day><Hour>11</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39133434</ArticleId><ArticleId IdType="doi">10.1007/s12035-024-04421-z</ArticleId><ArticleId IdType="pii">10.1007/s12035-024-04421-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Long COVID: let patients help define long-lasting COVID symptoms. Nature 586, 170, https://doi.org/10.1038/d41586-020-02796-2 (2020).</Citation></Reference><Reference><Citation>Perego, E. et al. Why the patient-made term &#x2018;long covid&#x2019; is needed [version 1; peer review: 1 approved with reservations, 1 not approved]. Wellcome Open Research 5, https://doi.org/10.12688/wellcomeopenres.16307.1 (2020).</Citation></Reference><Reference><Citation>Raveendran AV, Jayadevan R, Sashidharan S (2021) Long COVID: an overview. Diabetes Metab Syndr 15:869&#x2013;875. https://doi.org/10.1016/j.dsx.2021.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId><ArticleId IdType="pmc">8056514</ArticleId></ArticleIdList></Reference><Reference><Citation>Gy&#xf6;ngy&#xf6;si M et al (2023) Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases. Cardiovasc Res 119:336&#x2013;356. https://doi.org/10.1093/cvr/cvac115</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvac115</ArticleId><ArticleId IdType="pubmed">35875883</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ (2023) Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21:133&#x2013;146. https://doi.org/10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId><ArticleId IdType="pmc">9839201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortona E, Buonsenso D, Carfi A, Malorni W (2021) Long COVID: an estrogen-associated autoimmune disease? Cell Death Discov 7:77. https://doi.org/10.1038/s41420-021-00464-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-021-00464-6</ArticleId><ArticleId IdType="pubmed">33850105</ArticleId><ArticleId IdType="pmc">8042352</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi N (2020) Long covid: how to define it and how to manage it. BMJ 370:m3489. https://doi.org/10.1136/bmj.m3489</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3489</ArticleId><ArticleId IdType="pubmed">32895219</ArticleId></ArticleIdList></Reference><Reference><Citation>Diexer S et al (2023) Association between virus variants, vaccination, previous infections, and post-COVID-19 risk. Int J Infect Dis 136:14&#x2013;21. https://doi.org/10.1016/j.ijid.2023.08.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.08.019</ArticleId><ArticleId IdType="pubmed">37634619</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedberg P, Naucl&#xe9;r P (2023) Post&#x2013;COVID-19 condition after SARS-CoV-2 infections during the Omicron surge vs the Delta, Alpha, and wild type periods in Stockholm. Sweden The Journal of Infectious Diseases 229:133&#x2013;136. https://doi.org/10.1093/infdis/jiad382</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad382</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ (2022) Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 399:2263&#x2013;2264. https://doi.org/10.1016/s0140-6736(22)00941-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(22)00941-2</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId><ArticleId IdType="pmc">9212672</ArticleId></ArticleIdList></Reference><Reference><Citation>Canas LS et al (2023) Profiling post-COVID-19 condition across different variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations. Lancet Digit Health 5:e421&#x2013;e434. https://doi.org/10.1016/s2589-7500(23)00056-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2589-7500(23)00056-0</ArticleId><ArticleId IdType="pubmed">37202336</ArticleId><ArticleId IdType="pmc">10187990</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M (2022) Pathological sequelae of long-haul COVID. Nat Immunol 23:194&#x2013;202. https://doi.org/10.1038/s41590-021-01104-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId><ArticleId IdType="pmc">9127978</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempuraj, D. et al. COVID-19 and long COVID: disruption of the neurovascular unit, blood-brain barrier, and tight junctions. Neuroscientist, 10738584231194927, https://doi.org/10.1177/10738584231194927 (2023).</Citation></Reference><Reference><Citation>Krishnakumar HN et al (2023) Pathogenesis and progression of anosmia and dysgeusia during the COVID-19 pandemic. Eur Arch Otorhinolaryngol 280:505&#x2013;509. https://doi.org/10.1007/s00405-022-07689-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-022-07689-w</ArticleId><ArticleId IdType="pubmed">36209486</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai X et al (2023) Neurological complications of COVID-19. QJM 116:161&#x2013;180. https://doi.org/10.1093/qjmed/hcac272</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcac272</ArticleId><ArticleId IdType="pubmed">36484692</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J et al (2021) Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci 24:168&#x2013;175. https://doi.org/10.1038/s41593-020-00758-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00758-5</ArticleId><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L et al (2021) SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther 6:337. https://doi.org/10.1038/s41392-021-00719-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00719-9</ArticleId><ArticleId IdType="pubmed">34489403</ArticleId><ArticleId IdType="pmc">8419672</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang AJ et al (2021) Severe acute respiratory syndrome coronavirus 2 infects and damages the mature and immature olfactory sensory neurons of hamsters. Clin Infect Dis 73:e503&#x2013;e512. https://doi.org/10.1093/cid/ciaa995</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa995</ArticleId><ArticleId IdType="pubmed">32667973</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryche B et al (2020) Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters. Brain Behav Immun 89:579&#x2013;586. https://doi.org/10.1016/j.bbi.2020.06.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.06.032</ArticleId><ArticleId IdType="pubmed">32629042</ArticleId><ArticleId IdType="pmc">7332942</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L et al (2020) Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370:856&#x2013;860. https://doi.org/10.1126/science.abd2985</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd2985</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId><ArticleId IdType="pmc">7857391</ArticleId></ArticleIdList></Reference><Reference><Citation>Butowt R, von Bartheld CS (2022) The route of SARS-CoV-2 to brain infection: have we been barking up the wrong tree? Mol Neurodegener 17:20. https://doi.org/10.1186/s13024-022-00529-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00529-9</ArticleId><ArticleId IdType="pubmed">35292068</ArticleId><ArticleId IdType="pmc">8922388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilinska K, von Bartheld CS, Butowt R (2021) Expression of the ACE2 virus entry protein in the nervus terminalis reveals the potential for an alternative route to brain infection in COVID-19. Front Cell Neurosci 15:674123. https://doi.org/10.3389/fncel.2021.674123</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.674123</ArticleId><ArticleId IdType="pubmed">34290590</ArticleId><ArticleId IdType="pmc">8287262</ArticleId></ArticleIdList></Reference><Reference><Citation>M Cascella, M. R., A. Aleem, S C Dulebohn and R Di Napoli. Features, evaluation, and treatment of coronavirus (COVID-19), 2023).</Citation></Reference><Reference><Citation>Parker CG, Dailey MJ, Phillips H, Davis EA (2020) Central sensory-motor crosstalk in the neural gut-brain axis. Auton Neurosci 225:102656. https://doi.org/10.1016/j.autneu.2020.102656</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autneu.2020.102656</ArticleId><ArticleId IdType="pubmed">32151980</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers MM et al (2020) SARS-CoV-2 productively infects human gut enterocytes. Science 369:50&#x2013;54. https://doi.org/10.1126/science.abc1669</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1669</ArticleId><ArticleId IdType="pubmed">32358202</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Li Z, Yang C, Liu C (2021) The role of gut-brain axis in SARA-CoV-2 neuroinvasion: culprit or innocent bystander? Brain Behav Immun 94:476&#x2013;477. https://doi.org/10.1016/j.bbi.2021.01.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.01.024</ArticleId><ArticleId IdType="pubmed">33600935</ArticleId><ArticleId IdType="pmc">7883713</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q-L et al (2022) Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives. Mil Med Res 9:26. https://doi.org/10.1186/s40779-022-00386-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-022-00386-z</ArticleId><ArticleId IdType="pubmed">35676737</ArticleId><ArticleId IdType="pmc">9178901</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan D et al (2021) Neurological complications and infection mechanism of SARS-COV-2. Signal Transduct Target Ther 6:406. https://doi.org/10.1038/s41392-021-00818-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00818-7</ArticleId><ArticleId IdType="pubmed">34815399</ArticleId><ArticleId IdType="pmc">8609271</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R et al (2020) The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front Neurol 11:573095. https://doi.org/10.3389/fneur.2020.573095</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.573095</ArticleId><ArticleId IdType="pubmed">33551947</ArticleId></ArticleIdList></Reference><Reference><Citation>Messlinger K, Neuhuber W, May A (2022) Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19. Cephalalgia 42:176&#x2013;180. https://doi.org/10.1177/03331024211036665</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03331024211036665</ArticleId><ArticleId IdType="pubmed">34407648</ArticleId></ArticleIdList></Reference><Reference><Citation>Paniz-Mondolfi A et al (2020) Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol 92:699&#x2013;702. https://doi.org/10.1002/jmv.25915</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25915</ArticleId><ArticleId IdType="pubmed">32314810</ArticleId><ArticleId IdType="pmc">7264598</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM (2020) Deleterious outcomes in long-hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem Neurosci 11:4017&#x2013;4020. https://doi.org/10.1021/acschemneuro.0c00725</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00725</ArticleId><ArticleId IdType="pubmed">33275404</ArticleId></ArticleIdList></Reference><Reference><Citation>von Weyhern CH, Kaufmann I, Neff F, Kremer M (2020) Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet 395:e109. https://doi.org/10.1016/s0140-6736(20)31282-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)31282-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaunmuktane Z et al (2020) Microvascular injury and hypoxic damage: emerging neuropathological signatures in COVID-19. Acta Neuropathol 140:397&#x2013;400. https://doi.org/10.1007/s00401-020-02190-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02190-2</ArticleId><ArticleId IdType="pubmed">32638079</ArticleId><ArticleId IdType="pmc">7340758</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhea EM et al (2021) The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci 24:368&#x2013;378. https://doi.org/10.1038/s41593-020-00771-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00771-8</ArticleId><ArticleId IdType="pubmed">33328624</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubell J (2024) People with a connective tissue disorder may be especially vulnerable to the endothelial damage that characterizes long COVID due to the fragility of their vasculature and slow wound healing. Angiogenesis 27:123&#x2013;124. https://doi.org/10.1007/s10456-024-09908-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10456-024-09908-w</ArticleId><ArticleId IdType="pubmed">38319491</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauti, R. et al. Effect of SARS-CoV-2 proteins on vascular permeability. Elife 10, https://doi.org/10.7554/eLife.69314 (2021).</Citation></Reference><Reference><Citation>Ashour L (2023) Roles of the ACE/Ang II/AT1R pathway, cytokine release, and alteration of tight junctions in COVID-19 pathogenesis. Tissue Barriers 11:2090792. https://doi.org/10.1080/21688370.2022.2090792</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21688370.2022.2090792</ArticleId><ArticleId IdType="pubmed">35726726</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JY, Park JH, Jo C, Kim KC, Koh YH (2022) SARS-CoV-2 spike S1 subunit protein-mediated increase of beta-secretase 1 (BACE1) impairs human brain vessel cells. Biochem Biophys Res Commun 626:66&#x2013;71. https://doi.org/10.1016/j.bbrc.2022.07.113</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2022.07.113</ArticleId><ArticleId IdType="pubmed">35970046</ArticleId><ArticleId IdType="pmc">9349051</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini L et al (2020) SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids. Cell Stem Cell 27:951-961.e955. https://doi.org/10.1016/j.stem.2020.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.10.001</ArticleId><ArticleId IdType="pubmed">33113348</ArticleId><ArticleId IdType="pmc">7553118</ArticleId></ArticleIdList></Reference><Reference><Citation>Deffner F et al (2020) Histological evidence for the enteric nervous system and the choroid plexus as alternative routes of neuroinvasion by SARS-CoV2. Front Neuroanat 14:596439. https://doi.org/10.3389/fnana.2020.596439</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2020.596439</ArticleId><ArticleId IdType="pubmed">33122999</ArticleId><ArticleId IdType="pmc">7573115</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YH, Jiang D, Huang JT (2020) SARS-CoV-2 detected in cerebrospinal fluid by PCR in a case of COVID-19 encephalitis. Brain Behav Immun 87:149. https://doi.org/10.1016/j.bbi.2020.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.05.012</ArticleId><ArticleId IdType="pubmed">32387508</ArticleId><ArticleId IdType="pmc">7202824</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng, A. et al. Pathogenesis underlying neurological manifestations of long COVID syndrome and potential therapeutics. Cells 12, https://doi.org/10.3390/cells12050816 (2023).</Citation></Reference><Reference><Citation>Ong, I. Z., Kolson, D. L. &amp; Schindler, M. K. Mechanisms, effects, and management of neurological complications of post-acute sequelae of COVID-19 (NC-PASC). Biomedicines 11, https://doi.org/10.3390/biomedicines11020377 (2023).</Citation></Reference><Reference><Citation>Ryan FJ et al (2022) Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med 20:26. https://doi.org/10.1186/s12916-021-02228-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02228-6</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId><ArticleId IdType="pmc">8758383</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C et al (2022) Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 23:210&#x2013;216. https://doi.org/10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz MAF et al (2022) Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome. Front Cell Infect Microbiol 12:922422. https://doi.org/10.3389/fcimb.2022.922422</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId><ArticleId IdType="pmc">9279918</ArticleId></ArticleIdList></Reference><Reference><Citation>Arun S, Storan A, Myers B (2022) Mast cell activation syndrome and the link with long COVID. Br J Hosp Med (Lond) 83:1&#x2013;10. https://doi.org/10.12968/hmed.2022.0123</Citation><ArticleIdList><ArticleId IdType="doi">10.12968/hmed.2022.0123</ArticleId><ArticleId IdType="pubmed">35938771</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock LB et al (2021) Mast cell activation symptoms are prevalent in Long-COVID. Int J Infect Dis 112:217&#x2013;226. https://doi.org/10.1016/j.ijid.2021.09.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.043</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId><ArticleId IdType="pmc">8459548</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK et al (2021) Persistence of SARS CoV-2 S1 Protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front Immunol 12:746021. https://doi.org/10.3389/fimmu.2021.746021</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.746021</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Etter MM et al (2022) Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study. Nat Commun 13:6777. https://doi.org/10.1038/s41467-022-34068-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34068-0</ArticleId><ArticleId IdType="pubmed">36351919</ArticleId><ArticleId IdType="pmc">9645766</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG (2022) Early clues regarding the pathogenesis of long-COVID. Trends Immunol 43:268&#x2013;270. https://doi.org/10.1016/j.it.2022.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2022.02.008</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId><ArticleId IdType="pmc">8901423</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G et al (2021) Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun 4:100100. https://doi.org/10.1016/j.jtauto.2021.100100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId><ArticleId IdType="pmc">8049853</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E et al (2021) Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep Med 2:100288. https://doi.org/10.1016/j.xcrm.2021.100288</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100288</ArticleId><ArticleId IdType="pubmed">33969321</ArticleId><ArticleId IdType="pmc">8091032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY et al (2021) Diverse functional autoantibodies in patients with COVID-19. Nature 595:283&#x2013;288. https://doi.org/10.1038/s41586-021-03631-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Jammoul M et al (2023) Investigating the possible mechanisms of autonomic dysfunction post-COVID-19. Auton Neurosci 245:103071. https://doi.org/10.1016/j.autneu.2022.103071</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autneu.2022.103071</ArticleId><ArticleId IdType="pubmed">36580747</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibert FS et al (2023) Severity of neurological Long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors. Autoimmun Rev 22:103445. https://doi.org/10.1016/j.autrev.2023.103445</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2023.103445</ArticleId><ArticleId IdType="pubmed">37689093</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng M et al (2022) COVID-19 associated EBV reactivation and effects of ganciclovir treatment. Immun Inflamm Dis 10:e597. https://doi.org/10.1002/iid3.597</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.597</ArticleId><ArticleId IdType="pubmed">35349757</ArticleId><ArticleId IdType="pmc">8959425</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold, J. E., Okyay, R. A., Licht, W. E. &amp; Hurley, D. J. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens 10, https://doi.org/10.3390/pathogens10060763 (2021).</Citation></Reference><Reference><Citation>Su Y et al (2022) Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185:881-895.e820. https://doi.org/10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId><ArticleId IdType="pmc">8786632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Pablos, M., Paiva, B., Montero-Mateo, R., Garcia, N. &amp; Zabaleta, A. Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome. Frontiers in Immunology 12, https://doi.org/10.3389/fimmu.2021.656797 (2021).</Citation></Reference><Reference><Citation>Klein, J. et al. Distinguishing features of long COVID identified through immune profiling. medRxiv, https://doi.org/10.1101/2022.08.09.22278592 (2022).</Citation></Reference><Reference><Citation>Lai, Y. J. et al. Biomarkers in long COVID-19: a systematic review. Front Med (Lausanne) 10, 1085988, https://doi.org/10.3389/fmed.2023.1085988 (2023).</Citation></Reference><Reference><Citation>L&#xf3;pez-Hern&#xe1;ndez Y et al (2023) The plasma metabolome of long COVID patients two years after infection. Sci Rep 13:12420. https://doi.org/10.1038/s41598-023-39049-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-39049-x</ArticleId><ArticleId IdType="pubmed">37528111</ArticleId><ArticleId IdType="pmc">10394026</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito S et al (2024) Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome. Front Immunol 15:1341843. https://doi.org/10.3389/fimmu.2024.1341843</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1341843</ArticleId><ArticleId IdType="pubmed">38304426</ArticleId><ArticleId IdType="pmc">10830702</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S et al (2024) Cerebrospinal fluid metabolomic and proteomic characterization of neurologic post-acute sequelae of SARS-CoV-2 infection. Brain Behav Immun 115:209&#x2013;222. https://doi.org/10.1016/j.bbi.2023.10.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2023.10.016</ArticleId><ArticleId IdType="pubmed">37858739</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur KT et al (2021) COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain 144:2696&#x2013;2708. https://doi.org/10.1093/brain/awab148</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab148</ArticleId><ArticleId IdType="pubmed">33856027</ArticleId><ArticleId IdType="pmc">8083258</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje M, Iwasaki A (2022) The neurobiology of long COVID. Neuron 110:3484&#x2013;3496. https://doi.org/10.1016/j.neuron.2022.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.10.006</ArticleId><ArticleId IdType="pubmed">36288726</ArticleId><ArticleId IdType="pmc">9537254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E et al (2021) Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol 20:172. https://doi.org/10.1186/s12933-021-01359-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId><ArticleId IdType="pmc">8381139</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar, L. M. et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Biosci Rep 41, 10.1042/bsr20210611 (2021).</Citation></Reference><Reference><Citation>Ryu, J. K. et al. SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy. bioRxiv, https://doi.org/10.1101/2021.10.12.464152 (2021).</Citation></Reference><Reference><Citation>Bouck EG et al (2021) COVID-19 and sepsis are associated with different abnormalities in plasma procoagulant and fibrinolytic activity. Arterioscler Thromb Vasc Biol 41:401&#x2013;414. https://doi.org/10.1161/atvbaha.120.315338</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/atvbaha.120.315338</ArticleId><ArticleId IdType="pubmed">33196292</ArticleId></ArticleIdList></Reference><Reference><Citation>Jana, A. K., Greenwood, A. B. &amp; Hansmann, U. H. E. Presence of a SARS-COV-2 protein enhances amyloid formation of serum amyloid A. bioRxiv, https://doi.org/10.1101/2021.05.18.444723 (2021).</Citation></Reference><Reference><Citation>Matschke J et al (2020) Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. The Lancet Neurology 19:919&#x2013;929. https://doi.org/10.1016/S1474-4422(20)30308-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30308-2</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId><ArticleId IdType="pmc">7535629</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda, A. et al. Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain. bioRxiv, https://doi.org/10.1101/2022.01.07.475453 (2022).</Citation></Reference><Reference><Citation>Samudyata et al (2022) SARS-CoV-2 promotes microglial synapse elimination in human brain organoids. Mol Psychiatry 27:3939&#x2013;3950. https://doi.org/10.1038/s41380-022-01786-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01786-2</ArticleId><ArticleId IdType="pubmed">36198765</ArticleId><ArticleId IdType="pmc">9533278</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonhenry D et al (2024) SARS-CoV-2 infection as a cause of neurodegeneration. Lancet Neurol 23:562&#x2013;563. https://doi.org/10.1016/s1474-4422(24)00178-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(24)00178-9</ArticleId><ArticleId IdType="pubmed">38760096</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>